2021
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal Of The National Cancer Institute 2021, 113: 1369-1378. PMID: 33729494, PMCID: PMC8486331, DOI: 10.1093/jnci/djab034.Peer-Reviewed Original ResearchConceptsLong-term survivorsShort-term survivorsQuality of lifeOvarian cancer survivalLong-term survivalAdverse eventsCancer survivalBaseline QOLCancer Therapy-OvarianTrial Outcome IndexMeaningful prognostic valueLongitudinal mixed modelsAE gradeRobust prognosticatorPatient characteristicsPrognostic valueQoL changesSurvivor groupGOG 218Prognostic relationshipOutcome indexTrial designFunctional assessmentCare implicationsChange scores
2016
Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer
English DP, Menderes G, Black J, Schwab CL, Santin AD. Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer. Expert Review Of Molecular Diagnostics 2016, 16: 769-782. PMID: 27169329, DOI: 10.1080/14737159.2016.1188692.Peer-Reviewed Original ResearchConceptsChemo-resistant diseaseOvarian cancerMolecular profilingOptimal cytoreductive surgeryRecurrent ovarian cancerEpithelial ovarian cancerLong non-coding RNA expressionLong-term survivalAbsence of improvementCancer stem cellsStem cell markersAdjuvant chemotherapyCytoreductive surgeryNon-coding RNA expressionCancer 5Gynecologic tumorsMEDLINE searchNew agentsMolecular mediatorsTerm survivalCancerCell markersDiseaseRNA expressionChromosomal aberrations
2011
Eradication of chemotherapy‐resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin
Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin‐Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD. Eradication of chemotherapy‐resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin. Cancer 2011, 117: 5519-5528. PMID: 21692061, PMCID: PMC3701957, DOI: 10.1002/cncr.26215.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnimalsCarcinoma, Ovarian EpithelialCell Line, TumorChlorocebus aethiopsClaudin-3ClaudinsClostridium perfringensEnterotoxinsFemaleFlow CytometryHumansHyaluronan ReceptorsInjections, IntraperitonealMiceMice, SCIDMiddle AgedNeoplasms, Glandular and EpithelialNeoplastic Stem CellsOvarian NeoplasmsReal-Time Polymerase Chain ReactionVero CellsXenograft Model Antitumor AssaysConceptsOvarian cancer stem cellsCancer stem cellsClostridium perfringens enterotoxinCPE-induced cytotoxicityIntraperitoneal administrationStem cellsC.B-17/SCID miceChemotherapy-resistant cancer stem cellsHuman ovarian cancer stem cellsPerfringens enterotoxinClaudin-4 genesStem cell linesLong-term survivalOvarian cancer cellsReal-time polymerase chain reactionTight junction proteinsHigh-affinity receptorMultiple intraperitoneal administrationCancer stem cell linesPolymerase chain reactionSmall-interfering RNACell xenograftsSCID miceSignificant inhibitory effectChemotherapy resistance